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been approved for non-alcoholic fatty liver disease (NAFLD).
Sirt1hep/ mice, the beneficial effects of a PARPi-supplemented
HFHS diet were found to be Sirt1-dependent.The aim of the present study was to evaluate the therapeutic
potential of poly ADP-ribose polymerase (PARP) inhibitors in
mouse models of NAFLD.
Methods: As poly ADP-ribosylation (PARylation) of proteins
by PARPs consumes nicotinamide adenine dinucleotide (NAD+),
we hypothesized that overactivation of PARPs drives NAD+
depletion in NAFLD. Therefore, we assessed the effectiveness of
PARP inhibition to replenish NAD+ and activate NAD+-
dependent sirtuins, hence improving hepatic fatty acid oxidation.
To do this, we examined the preventive and therapeutic benefits
of the PARP inhibitor (PARPi), olaparib, in different models of
NAFLD.
Results: The induction of NAFLD in C57BL/6J mice using a high-
fat high-sucrose (HFHS)-diet increased PARylation of proteins
by PARPs. As such, increased PARylation was associated with
reduced NAD+ levels and mitochondrial function and content,
which was concurrent with elevated hepatic lipid content. HFHS
diet supplemented with PARPi reversed NAFLD through repletion
of NAD+, increasing mitochondrial biogenesis and b-oxidation in
liver. Furthermore, PARPi reduced reactive oxygen species, endo-
plasmic reticulum stress and fibrosis. The benefits of PARPi treat-
ment were confirmed in mice fed with a methionine- and
choline-deficient diet and in mice with lipopolysaccharide-
induced hepatitis; PARP activation was attenuated and the
development of hepatic injury was delayed in both models. UsingJournal of Hepatology 20
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Lay summary: Non-alcoholic fatty liver disease (NAFLD) is now
considered to be the most common liver disease in the Western
world and has no approved pharmacological therapy. PARP inhi-
bitors given as a treatment in two different mouse models of
NAFLD confer a protection against its development. PARP inhibi-
tors may therefore represent a novel and practical pharmacolog-
ical approach for treating NAFLD.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD) is now considered to be
themost common liver disease in theWesternworld [1]. NAFLD is
quickly becoming an important public health concern due to the
rising incidence of obesity in both children and adults [2]. The
disease spectrum for NAFLD ranges from simple fatty liver
(steatosis), to non-alcoholic steatohepatitis (NASH), cirrhosis,
hepatocellular carcinoma, and finally it may result in liver-
related death [3,4]. Moreover, as the prevalence of NAFLD
escalates, NASH-related cirrhosis and hepatocellular carcinoma
will increasingly become a major health care problem and a
primary indication for liver transplantation [5,6]. Currently, the
principal treatment for NAFLD/NASH is lifestyle modification by
diet and exercise [7,8]. However, pharmacological therapy is
indispensable as obese patients with NAFLD often have difficulty
in maintaining improved lifestyles. In this context, farnesoid
X receptor or peroxisome proliferator-activated receptor-a
activators are currently being tested in clinical trials, but they
are not yet approved [9].17 vol. 66 j 132–141
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In the early stages of NAFLD, liver-specific metabolic adapta-
tions lead to increased liver fat load from the periphery [10],
which may promote mitochondrial dysfunction upon chronic
fat accumulation [11]. Studies performed in humans and rodents
have demonstrated that enzymatic activities involved in oxida-
tive phosphorylation (OXPHOS) are reduced in NAFLD
[10,12,13]. The major consequence of reduced OXPHOS activity
is a reduction in ATP generation [12]. Another aspect associated
with mitochondrial dysfunction in NAFLD is an increase in reac-
tive oxygen species (ROS) production. This phenomenon is often
associated with elevated expression of several cytokines, promot-
ing an inflammatory state, which has been shown to be deleteri-
ous in NAFLD [14,15]. ROS has also been reported to impair
OXPHOS, thereby inhibiting b-oxidation and perpetuating the
continued progression of NAFLD [16].
Several recent studies indicate the potential involvement of
poly ADP-ribose polymerase (PARP) activity in promoting
metabolic dysfunction [17–20]. Interestingly, various metabolic
disorders have been associated with elevated oxidative stress
and DNA damage, which can subsequently induce PARP activ-
ity [21]. The hyperactivation of PARPs can initiate the pro-
grammed cell death pathway causing both ATP and
nicotinamide adenine dinucleotide (NAD+) depletion [22],
which reduces mitochondrial function and b-oxidation of fats
[18,19,21,23]. Interestingly, this correlation was also found in
the liver, as demonstrated by the negative correlation between
PARP1 and b-oxidation gene transcripts in normal human liver
datasets [11].
Being an important substrate for PARP activity, NAD+ is also
a critical component for various metabolic reactions in cells
[24]. For example, the sirtuin protein, Sirt1, regulates many
metabolic pathways, in adaptation to nutritional status. When
Sirt1 is active, during a state of energy deficit, it uses NAD+
as a co-substrate for the deacetylation of proteins [25]. As
NAD+ is rate-limiting for Sirt1, the consumption of NAD+ by
PARPs can lead to reduced sirtuin activity [19,24,26]. We have
previously shown that NAD+ levels progressively decline with
the development of NAFLD and postulated that this may be
due to enhanced PARP activity and enhanced competition with
Sirt1 for available NAD+ [11]. Given the lower Km for NAD+ by
PARP1 compared to Sirt1 this is a very likely scenario [24].
Based on these observations, the inhibition of PARP activity
may represent a promising approach to counteract the devel-
opment of NAFLD by increasing NAD+ levels and activating
Sirt1-directed mitochondrial biogenesis and b-oxidation of fatty
acids.
In this study, we demonstrate that a long-term high-fat high-
sucrose (HFHS) diet can induce hepatic PARylation, via increased
PARP activity, having a deleterious effect on NAD+/Sirtuin-
directed metabolism, resulting in the development of NAFLD.
By treating mice with a PARP inhibitor (PARPi) in a preventive
and therapeutic manner, we were able to arrest or reverse the
development of NAFLD. Moreover, using a liver-specific Sirt1
knockout mouse line (Sirt1hep/), we demonstrated that the
PARPi-mediated protection against NAFLD development was
dependent on hepatic Sirt1 expression. This protective effect of
PARP inhibition against NAFLD was also confirmed using a
methionine- and choline-deficient (MCD) diet, as another mouse
model of NAFLD. Finally, we showed the benefit of PARP inhibi-
tion against lipopolysaccharide (LPS)-induced acute hepatitis in
mice.Journal of Hepatology 201Materials and methods
Animal experiments
All animal experiments were performed according to Swiss, South Korean and EU
ethical guidelines and approved by the local animal experimentation committee
of the Canton de Vaud under license #2868 and the Committee on the Ethics of
Animal Experiments of Chungnam National University Graduate School of Medi-
cine (CNUH-015-A0001). Detailed experimental protocols are provided in the
Supplementary Materials and Methods.
Generation of Sirt1hep/ mice
Generation of Sirt1L2/L2 mice has been previously described [27]. Liver-specific
Sirt1 knockout mice were generated by breeding Sirt1L2/L2 mice with mouse albu-
min (Alb)-Cre mice (AlbcreTg/0) [28], both of which have been backcrossed to
C57BL/6J mice for 10 generations. These mice lines were then further intercrossed
to generate mutant AlbcreTg/0/Sirt1L2/L2 mice, which were termed Sirt1hep/ mice.
Sirt1hep/ and Sirt1L2/L2 mice were fed with HFHS pellets containing vehicle
(DMSO) or olaparib (PARP inhibitor, GP0126, Glentham Life Sciences, 50 mg/kg/
day) for 18 weeks.
Histology and liver function
Preparation of histological tissue sections, staining procedures for hematoxylin
and eosin (H&E), Oil Red O, Sirius Red, cytochrome c oxidase activity, succinate
dehydrogenase activity and CD45 are described in the Supplementary Materials
and Methods. Mitochondrial function in fresh liver tissue was evaluated with
Western blotting, high-resolution respirometry [29], and BN-PAGE analysis [30],
as described in the Supplementary Materials and Methods. Evaluation of global
PARylation in fresh liver tissue was performed as previously described [19].
Quantification of NAD+ and adenosine triphosphate levels
NAD+ was isolated using acidic then alkaline extraction methods. Tissue NAD+
was analysed with mass spectrometry, as previously described [11,31]. Total ade-
nosine triphosphate (ATP) content was measured by the CellTiter-Glo lumines-
cent cell viability assays (Promega). Typically, luminescence was recorded with
a Victor X4 plate reader (PerkinElmer, Waltham, MA), and values were normal-
ized by the total protein concentration, determined using a Bradford assay.
Liver triglyceride, cholesterol, and lipid peroxidation measurements
Hepatic lipids were extracted as described previously [32]. Triglyceride (TG) and
cholesterol contents in hepatic lipid fractions were quantified using enzymatic
assays (Roche). The by-product of lipid peroxidation (LPO) and a marker of oxida-
tive stress, 4-hydroxynonenal (HNE), was measured following the manufacturer’s
protocol of the OxiSelect HNE-His Adduct enzyme-linked immunosorbent assay
Kit (Cell Biolabs Inc., San Diego, CA).
Bioinformatic analyses
All raw transcriptomic data are publicly available on Gene Expression Omnibus
(GEO; www.ncbi.nlm.nih.gov/geo) under the accession numbers GSE48452,
GSE24031, GSE28619 and GSE50579 or on GeneNetwork (www.genenetwork.
org). Heatmaps were built using GENE-E (The Broad institute, www.broadinsti-
tute.org/cancer/software/GENE-E/) Principal component analysis, corrgram and
correlation network were accomplished using functions and packages in R
(www.r-project.org). The depth of the shading at the correlation matrices
(corrgram) indicates the magnitude of the correlation (Pearson’s r). Positive and
negative correlations within the corrgram and correlation network are repre-
sented in blue and red, respectively. Only correlations with a p <1  105 are
displayed in the correlation network.
Statistical analysis
Statistical analysis was performed with Prism software (version 6.0; GraphPad
Software Inc.). The significance of differences between two groups was deter-
mined by unpaired two-tailed Student t test. For comparison of multiple groups,
we applied a one-way analysis of variance (ANOVA) with a post-hoc Bonferroni7 vol. 66 j 132–141 133
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test. Results are presented as mean ± standard error of the mean (SEM). A p
value <0.05 was considered significant.Results
PARylation and PARP expression positively correlate to NAFLD
indicators in both humans and mice
To understand the nature of the role of PARPs in the development
of human NAFLD, we first analysed human transcriptomes from a
cohort of patients with NAFLD that included 40 samples
(GSE48452) deposited in the NCBI GEO database [33]. These data
demonstrate an increased expression of inflammatory and fibro-
genic genes in liver tissues from patients with NASH, clearly indi-
cating the pathology of NAFLD (Fig. 1A). In addition, the induction
of PARP transcripts, including PARP1, the most abundant PARP
transcript and active NAD+ consuming enzyme in mice [23],
occurs in the group of patients with NASH (Fig. 1A). Using a prin-PARP15
PARP3
PARP6
CTGF
PARP11
PARP14
MMP12
PARP1
PARP9
PARP4
PARP8
TGFB1
CCL2
TLR2
PARP12
CCR2
COL1A1
COL1A2
COL3A1
VIM
MMP2
TNF
MMP9
PARP16
PARP2
PRDX3
PARP10
MMP13
MMP3
Normal NASH
GSE48452 
Hi
Lo
A
Fibro.PCA
PARP1
PARP10
P
PARP1
PARP
PARP15
PARP16
PARP2
PARP3
PARP9
−2
0
2
−2 0 2
PC1 (28.1%)
PC
2 
(2
0.
7%
)
PARP6
B
FibroPCA
PARP1
PARP2
PARP9
PARP14
PARP15
ARP16
PTGS2
SO
PARP3
P
C
Normal ASH
PARP2
PARP3
PARP6
PARP8
PARP1
PARP13
PARP4
PARP11
PARP9
PARP12
PARP10
PARP16
PARP14
GSE28619
Hi
Lo
E C HCC-G2
GSE50579
F
Fig. 1. Correlations between PARP transcripts and markers of inflammation or fibros
NAFLD. (A) Heatmap displaying the relative expression of PARPs and genes known to be
per group; dataset GSE48452). (B) Principal component analysis (PCA) plot showing
fibrogenic genes in Fig. 1A and taken from the NASH subject datasets [33]. (C) Corrgra
selected anti-oxidant genes from the described NASH subjects [33]. (D) Correlation net
derived from the GTEx project dataset (GSE45878, genenetwork.org). Only correlations w
PARPs in patients with alcoholic steatohepatitis (E; normal control, n = 8; ASH, n = 14; d
n = 3; HCC-grade 2 (HCC-G2), n = 9; dataset GSE50579) (G) HFHS-induced global PARyla
134 Journal of Hepatology 201cipal component analysis (PCA) we confirmed that the majority
of PARP transcripts (in blue, Fig. 1B) have a strong positive
correlation with fibrogenic genes (Fibro. PCA, Fig. 1B). Of note,
anti-oxidant genes have negative correlations with PARP and
fibrogenic genes (Fig. 1C). PARP, fibrogenic and inflammatory
genes were also closely clustered as a gene network, suggesting
that this strong relationship might promote the development of
a fatty liver (Fig. 1D). Furthermore, PARP transcripts were
increased in datasets from other liver diseases, including
alcoholic liver disease (GSE28619) [34] and hepatocellular
carcinoma (GSE50579) (Fig. 1E and F) [35].
In line with these findings, Parp1 transcript expression was
also elevated in a cohort of mice that were classified according
to their level of NAFLD induction when challenged with a high-
fat diet (HFD) (GSE24031, Supplementary Fig. 1) [36]. Mice clas-
sified as high-responders to a HFD (HFH), meaning that NAFLD
was more severe in these mice, expressed higher transcript levels
of the various Parps, including Parp1. Furthermore, we observed
that whole liver extracts from mice fed 18 weeks of a HFHS dietARP11
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(a Western style diet that leads to insulin resistance and adipos-
ity [37]) expressed higher levels of PARP1 and global protein
PARylation compared to chow diet (CD)-fed mice (Fig. 1G). All
together, these data suggest that the induction of PARP expres-
sion and activity likely plays an important role in the develop-
ment of NAFLD (and other liver diseases), leading us to
hypothesize that reducing PARP activity, with clinically available
PARP inhibitors, may help to attenuate the progression of NAFLD.
PARP inhibition improves fatty liver and systemic glucose
homeostasis
To test our hypothesis, we treated mice either at the onset of a
HFHS diet, in a preventive mode (starting at 7 weeks of age), or
9 weeks after the start of the diet, in a therapeutic mode (starting
at 16 weeks of age), by supplementing the diet with the PARPi,
olaparib (50 mg/kg/day). While food intake was not altered
(Supplementary Fig. 2A), supplementing the HFHS diet with
PARPi, in both preventive and therapeutic modes, reduced body,
liver and epididymal fat weights compared to HFHS-fed mice in
both preventive and therapeutic modes (Fig. 2A–C). In line with1 3 5 7 9 11 13 15
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Fig. 2. PARP inhibitor (PARPi) treatment protects against and reverses NAFLD, while
HFHS, HFHS + PARPi-Preventive (PARPi-Prev), or HFHS + PARPi-Therapeutic (PARPi-Ther)
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PARPi therapy improved glucose tolerance (OGTT) (H) and plasma insulin levels (I) after a
insulin tolerance test (ITT), measured after 16 weeks of diet. (n = 8–10). ⁄, #, $ p <0.05;
expressed as the mean ± SEM. One-way ANOVA with a post-hoc Bonferroni test was us
Journal of Hepatology 201this finding, hepatic TG and total cholesterol levels were also
reduced (Fig. 2D and E). These observations were concurrent to
improved gross liver morphology and coloration in PARPi treated
mice (Fig. 2F). Likewise, H&E and Oil Red O staining of liver tissue
sections exhibited the expected histological features of HFHS
diet-induced macrovesicular steatosis (Fig. 2G), which was atten-
uated by the administration of PARPi (Fig. 2G). PARPi treatment
improved the histological score for steatosis, and showed a sim-
ilar trend for the activity score, according to a blinded assessment
by a certified pathologist (Supplementary Fig. 2B and C). In addi-
tion glucose homeostasis and insulin sensitivity was ameliorated
in both preventive and therapeutic modes, as reflected by
improved glucose excursion and reduced insulin release during
an oral glucose tolerance test and the faster decline in glucose
levels during an insulin tolerance test (Fig. 2H–J). PARPi-
mediated protection from HFHS-induced hepatic injury was con-
firmed by reductions in plasma alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) (Supplementary Fig. 2D
and E). No toxicity was observed upon PARPi treatment, as
attested by normal kidney function, pancreatic and muscle
enzymes (Supplementary Fig. 2F–H). Collectively, multiple major.0
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clinical aspects of NAFLD were improved with PARP inhibition,
indicating the multifaceted effects of PARP overactivation in
NAFLD.
PARPi replenishes NAD+ and improves mitochondrial function
PARP activity is associated with the depletion of cellular NAD+,
leading to a reduction in sirtuin activity and impairment of mito-
chondrial function [21]. First, we performed in vitro experiments
using AML12 mouse hepatocytes and asked whether PARPi treat-
ment is sufficient to increase cellular NAD+ levels. Indeed, NAD+
levels were induced in AML12 cells treated with PARPi for 24 h
(Supplementary Fig. 3A). Meanwhile, PARPi also elevated mtDNA
copy number (Supplementary Fig. 3B). Consequently, there was
an induction of nuclear and mitochondrial DNA-encoded
OXPHOS proteins in PARPi treated AML12 cells (Supplementary
Fig. 3C).
Given that PARPi treatment can induce mitochondrial biogen-
esis in vitro by boosting intracellular NAD+ (Supplementary
Fig. 3A–C) and that a HFHS diet can induce the PARylation of pro-
teins (Fig. 1G), we proposed that the PARPi might replenish liver
NAD+ levels by arresting the induction of PARylation during
NAFLD. Indeed, HFHS-induced PARylation and NAD+ depletion
were both attenuated using either preventive or therapeutic
PARPi administration (Fig. 3A and B). To assess whether the
PARPi-induced restoration of NAD+ levels impacted on mitochon-
drial biogenesis and function, we performed several additional
analyses. First, we demonstrated that the ratio of mitochondrial
DNA relative to nuclear DNA (mtDNA/nDNA ratio) in liver was
higher in PARPi treated groups, indicating a higher mitochondrial
content (Supplementary Fig. 3D). In line with an increased
mtDNA copy number, we observed that PARPi treatment restored
OXPHOS complexes and ATP levels in HFHS-fed livers
(Fig. 3C and D), indicating an improvement in mitochondrial bio-
genesis and function. These observed beneficial effects on mito-
chondrial parameters were confirmed by increased cytochrome
c oxidase (COX) and succinate dehydrogenase (SDH) stains of
liver sections, reflecting complex IV and complex II activity,
respectively (Fig. 3E). PARPi induced Cpt1, Mcad, Acox1 and Cox5a
expression, while transcripts involved in lipogenesis, such as
Fasn, Acc and Scd1, were reduced (Fig. 3F and Supplementary
Fig. 3E). Taken together, the above findings demonstrate that
PARPi therapy attenuates the consumption of NAD+ by PARyla-
tion and improves the b-oxidation of fatty acids.mice were used in these experiments.PARP inhibition resolves hepatic endoplasmic reticulum stress and
inflammation in HFHS-fed mice
Endoplasmic reticulum (ER) stress is critical to the initiation and
integration of inflammatory pathways [38]. In human subjects
with NAFLD, the activation of ER stress has been shown to corre-
late with histological severity [39]. Both the activating transcrip-
tion factor 4 (ATF4), which is a central mediator of the ER stress
pathway, and the CCAAT/enhancer-binding protein homologous
protein (CHOP, also known as DDIT3 or GADD153), a transcrip-
tion factor that is induced in response to a wide variety of cellular
stresses, including ER stress, cell cycle arrest and apoptosis
[40,41] contribute to hepatic inflammation [42,43]. As expected,
HFHS diet effectively triggered the ER unfolded protein response
(UPRer) at both the transcript and protein levels in mice
(Fig. 4A and B). Specifically, induction of the UPRer signaling136 Journal of Hepatology 201pathway, starting with ATF4, which transactivates both CHOP
and the promoter of the binding immunoglobulin protein (BiP)/
glucose-regulated protein 78 (GRP78) [38], was shown to have
higher protein and/or transcript expression in mice on a HFHS
diet for 18 weeks. PARPi administration was associated with a
decrease of these transcripts and protein markers of ER stress.
This effect is in line with a previously described treatment using
the NAD+ precursor nicotinamide riboside (NR) [11].
PARPi therapy arrested the induction of inflammatory genes,
such as Il1, Il6, Ccl2/Mcp-1 and Tnfa in animals on a HFHS diet
(Fig. 4C) [44]. These observations were in agreement with
reduced plasma tumor necrosis factor alpha (TNFa) levels
(Fig. 4D) and the infiltration of CD45-positive leukocytes into
the liver (Fig. 4E). Furthermore, the preventive and therapeutic
PARPi treatments similarly induced transcript levels of the
anti-oxidant genes Sod2, Cat, Gpx4 and Prdx3, compared to the7 vol. 66 j 132–141
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JOURNAL OF HEPATOLOGYreductions seen on a HFHS diet (Supplementary Fig. 3F). The
resulting anti-oxidant protection in PARPi treated mice was
validated by a decline in liver lipid peroxidation (Supplementary
Fig. 3G), a surrogate marker for oxidative stress [45]. Altogether
PARPi treatment conferred protection against the development
of ER stress, inflammation, and ROS production, each being essen-
tial markers for the pathogenesis of NAFLD.
PARPi therapy prevents fatty liver disease induced by an MCD diet
To validate PARP inhibition as a robust treatment for NAFLD, the
effect of PARPi was also examined in mice given an MCD diet.
Feeding mice with an MCD diet is known to induce severe liver
steatosis, inflammation, oxidative stress, and mitochondrial dam-
age, without the classical systemic features of NAFLD such as
insulin resistance [46]. At 10 weeks of age, male C57BL/6J mice
were challenged with an MCD diet for 5 weeks. Similar to the
effects seen in mice on a HFHS diet, MCD-fed mice treated with
PARPi in a preventive manner exhibited reduced PARylation
and increased hepatic NAD+ levels (Fig. 5A and B).
Mice fed with an MCD diet for 5 weeks showed classical
pathophysiological characteristics of NAFLD, including hepatic
steatosis, inflammation and fibrosis. MCD diet increased AST
and ALT levels compared to a control diet, while PARPi treatment
reduced their levels (Fig. 5C and D). The protective effect of PARPi
against MCD-induced liver damage was associated with
increased oxygen consumption rates, driven by complex I (and
trending with complex II) in the presence of ADP (Fig. 5E). This
improvement of mitochondrial function by PARPi was compli-
mented with an induction of Acox1, Mcad, Cpt1, Cox5a and Cox2
transcript levels (Fig. 5F), with reduced Oil Red O staining of liver
sections (Fig. 5G), and an improved steatosis, activity and fibrosis
score (SAF score) for steatosis and activity (Supplementary Fig. 4A
and B). This was matched with a reduction of ROS-induced dam-
age, as revealed by diminished levels of lipid peroxidation in
PARPi fed mice (Supplementary Fig. 4C).Journal of Hepatology 201Elevated hepatic expression of proinflammatory genes in MCD
diet-fed mice was significantly reduced with PARPi intervention
(Fig. 5F). These findings were confirmed by a reduction in CD45
positive stained cells in liver sections taken from PARPi treated
mice (Fig. 5G). In agreement, PARPi lowered the expression of
the fibrosis-related transcripts, Col1a1, Col2a1 and Col5a2, in con-
junction with a reduction in Sirius Red staining of liver sections
(Fig. 5G and Supplementary Fig. 4D). This affirms previous obser-
vations that revealed protection by PARPi treatment against
chemically induced hepatic fibrosis, in a context not linked to
NAFLD and NAD+ metabolism [47], demonstrating the potential
multifaceted benefits offered by PARPi therapy. Similar to the
HFHS experiment, we did not detect any signs of toxicity on
key organs, including kidney, pancreas and muscle (Supplemen-
tary Fig. 4E–G). Altogether, the reduced lipid hepatic content,
inflammation, lipid peroxidation and fibrosis in animals fed with
an MCD diet demonstrates the broad protective role of PARPi
therapy on the progression of NAFLD.
PARPi-induced mitochondrial biogenesis is Sirt1-dependent
We next tested the Sirt1-dependency of PARPi-induced mito-
chondrial biogenesis. In AML12 hepatocytes, the Sirt1 inhibitor,
EX527, blocked the Sirt1-mediated deacetylation of FOXO1 seen
with PARPi (Fig. 6A) in vitro. Along a similar line, we evaluated
the potential Sirt1-dependency for PARPi action ex vivo using
primary hepatocytes from Sirt1L2/L2 mice, infected with an
Ad-GFP (control) or Ad-Cre to induce a Sirt1 loss of function.
These experiments clearly demonstrate the Sirt1-dependency of
the induction of the mitochondrial-encoded MTCO1 protein
while the expression of the nuclear-encoded SDHA was not
altered (Fig. 6B). The contribution of Sirt1 in mediating the effects
of PARPi was next assessed in vivo using liver-specific
Sirt1-deficient mice (Sirt1hep/ mice) [27]. The Sirt1 dependency
of PARPi action was demonstrated by the blunted response of
liver and body weights in these Sirt1hep/ mice, after 18 weeks7 vol. 66 j 132–141 137
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Research Articleof PARPi/HFHS diet (Supplementary Fig. 5A and B). These effects
were complemented by the attenuation of the PARPi-mediated
improvements in hepatic TG accumulation and fibrosis (Fig. 6C
and Supplementary Fig. 5C), along with transcript levels in
b-oxidation, including Mcad, Cpt1 and Cox2, and mitochondrial
function, comprising of Sirt1, Tfam, Tomm40, Atp5g1 and Cytc, in
these Sirt1hep/ animals (Fig. 6D). These findings suggest that
Sirt1 is central to mediate the effects of PARPi on liver mitochon-
drial metabolism.
PARPi protects against LPS-induced acute hepatitis
To assess the potential of PARPi treatment in other liver diseases
we evaluated its potential effect against LPS-induced acute hep-
atitis. At 8 weeks of age, male C57BL/6J mice were injected i.p.
with LPS at 5 mg/kg of body weight. LPS injected mice exhibited
severe hepatitis and systemic inflammation, leading to increased
PARylation and NAD+ depletion in their liver, all of which was
alleviated by PARPi treatment (Fig. 7A and B). Plasma level of
ALT was reduced in PARPi treated mice when compared to non-
treated mice (Fig. 7C). Furthermore, PARPi treatment allowed
for a significant reduction of LPS-induced hepatic proinflamma-
tory genes Il-1b and Il-6 (Fig. 7D). This was corroborated by a
reduction in CD45-positive stained cells in liver sections taken
from PARPi treated mice compared to non-treated controls138 Journal of Hepatology 201(Fig. 7E). Altogether these observations showed that PARPi treat-
ment might have a protective effect on other liver diseases, such
as that of sepsis-induced acute hepatitis.Discussion
Despite that NAFLD is now a worldwide burden on health, the
exact pathophysiology and succession of events leading up to
lipid accumulation, inflammation and fibrosis is not clearly delin-
eated [14]. In particular, we recently described the progressive
decline in NAD+ homeostasis as a potential hallmark for NAFLD
severity [11]. However, the cause for the decline in NAD+ was,
until now, not elucidated. As PARP proteins are major NAD+ con-
sumers and have been implicated in inflammatory responses, a
common feature of NAFLD, we endeavored to profile the role of
PARylation as a result of PARP activation in the development of
NAFLD.
In a cohort of patients with NAFLD [33] we observed a nega-
tive correlation between transcript levels of several PARPs,
including PARP1, with that of anti-oxidant genes, while fibrogenic
genes were positively correlated. Furthermore, it was previously
shown that PARP transcripts are negatively correlated to NAMPT
and NRK1, two key enzymes involved in NAD+ biosynthesis, in
two independent normal human datasets and in the mouse7 vol. 66 j 132–141
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Journal of Hepatology 201BXD genetic reference population [11]. Liver Parp transcript
expression is therefore linked to markers of liver degeneration
during the progression of NAFLD. These changes in human liver
transcriptomes of patients with NAFLD were consistent with pro-
tein and enzymatic changes we observed in mouse models of
NAFLD, as mice fed a HFHS diet exhibited increased PARylation
and PARP1 expression matched with the depletion of liver
NAD+ levels. Altogether, these findings demonstrate a conserved
link between PARP1 expression, and the reduction of NAD+ levels
during the progression of NAFLD. We therefore hypothesized that
long-term PARP inhibition in HFHS-fed mice could recover NAD+
levels to activate sirtuins, which in turn would boost mitochon-
drial biogenesis and function, along with enhancing anti-
oxidant levels and reducing inflammatory responses.
Treating mice in preventive or therapeutic modes with PARPi
while on a HFHS diet recovered mitochondrial content and func-
tion leading to an increase in fatty acid b-oxidation and a reduc-
tion in hepatic lipid deposits. PARPi not only led to a marked
reduction in the severity of diet-induced hepatic steatosis, but
also improved glucose intolerance and systemic insulin resis-
tance. Interestingly, we observed that mice given an MCD diet
exhibited reduced b-oxidation gene expression, whereas mice
under a HFHS diet showed elevations of the same gene-set. This
suggests that the compensatory metabolic adaptations present in
mice given a HFHS diet were lost in MCD-fed mice that expressed
a more advanced stage of NAFLD [10].
The induction of mitochondrial biogenesis by PARPi was
shown to be Sirt1-dependent by using a Sirt1/ primary hepato-
cyte model. Similarly, feeding Sirt1hep/ mice with a HFHS diet
confirmed the SIRT1-dependent benefits of PARPi treatment.7 vol. 66 j 132–141 139
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The benefit of boosting NAD+ to induce Sirt1-dependent mito-
chondrial biogenesis, as presently observed with PARPi, was pre-
viously shown by our group by supplementing a HFHS diet with
the NAD+ precursor NR [11,27,48]. However, the process of
directly inhibiting PARPs, which are responsible for eliciting hep-
atic inflammation and fibrosis [49], may confer an advantage for
the use of PARPi therapies over that of NAD+ precursors. Alto-
gether PARP inhibition may provide a multi-pronged therapy
against NAFLD development by inhibiting the overactivation of
PARPs, and therefore inflammation and fibrosis, while also safe-
guarding NAD+ pools to activate Sirt1 and induce mitochondrial
biogenesis and function. Along with reduced mitochondrial func-
tion, excessive oxidative stress was observed in both human and
experimental models of hepatic steatosis and was suggested to be
a key feature in the progression of NAFLD [50]. This characteristic
increase in oxidative stress was recapitulated in the liver of
HFHS- and MCD-diet-fed mice, which was attenuated with PARPi
therapy, as revealed by the reduction in peroxidized unsaturated
lipids. Our study hence shows that PARPi treatment improves
mitochondrial function, reduces hepatic lipid accumulation, ER
stress and ROS generation as previously reported in human
NAFLD subjects following a bariatric surgery-induced weight loss,
which was similarly characterized by a reduction of hepatic
triglyceride content coincident to the attenuation of ER stress
[51].
Both bioinformatics studies in humans, as well as, experimen-
tal work in two mouse models that mimic several features of
human NAFLD [52], suggested that PARPs are involved in a wide
range of alterations that predispose to the development of
NAFLD. The manifestations of NAFLD, which can include abnor-
mal hepatic metabolism, steatosis, inflammation and fibrosis,
were all attenuated by PARPi treatment signifying the beneficial
role of PARPi in the setting of NAFLD. We further explored
whether PARPs were involved in other liver diseases. Our bioin-
formatics analysis suggested that increased PARP expression
may also be associated with the development of ASH and HCC.
We then extended the involvement of PARPs in multiple liver dis-
eases by showing that PARP activation was also involved in
sepsis-induced acute hepatitis and that PARP inhibition may like-
wise be beneficial as a treatment.
These findings emphasize the clinical relevance of PARP inhi-
bition, not only in the field of oncology, but also as a promising
therapeutic strategy for the treatment of NAFLD and potentially
other liver diseases. Furthermore, NAD+ balance was also shown
to play a major role in acute alcohol-induced liver injury, suggest-
ing that NAD+ maintenance through PARP inhibition may be fun-
damental to preserve hepatic homeostasis [53]. Altogether, these
observations have implications for the development of new
approaches to prevent and treat this increasingly common cause
of end-stage liver disease, PARP inhibitors are already FDA
approved for the treatment of several cancers, leading to the
potential rapid application of these pharmaceuticals for meta-
bolic disorders such as NAFLD.Financial support
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